A recent study exhibited that the expression of HOX is directly dependent on NPM1 mutants [15], making menin-KMT2A inhibition a potential therapeutic option in NPM1mut-AML (Figure 1), with efficacy seen in animal studies [63]. The gene discussed is NPM1; the disease is acute myeloid leukemia.